Login to Your Account



Aeterna Zentaris Inks $69.2M+ Japanese Perifosine Rights Deal

By Tom Wall


Thursday, March 10, 2011
Aeterna Zentaris Inc., of Quebec City, announced its third deal for development and commercialization of the company's lead cancer compound, perifosine, this one with Yakult Honsha Co. Ltd., of Tokyo, for $8.3 million up front, a potential $60.9 million in clinical and regulatory milestones in Japan, and double-digit royalties on Japanese net sales. Yakult Honsha will be responsible for the development, registration and commercialization in Japan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription